Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Cyclooxygenase-2 in oncogenesis.

Rizzo MT.

Clin Chim Acta. 2011 Apr 11;412(9-10):671-87. doi: 10.1016/j.cca.2010.12.026. Epub 2010 Dec 25. Review.

PMID:
21187081
2.
3.

Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?

Choy H, Milas L.

J Natl Cancer Inst. 2003 Oct 1;95(19):1440-52. Review.

PMID:
14519750
4.

Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.

Harris RE.

Subcell Biochem. 2007;42:93-126. Review.

PMID:
17612047
5.

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.

Grösch S, Maier TJ, Schiffmann S, Geisslinger G.

J Natl Cancer Inst. 2006 Jun 7;98(11):736-47. Review.

PMID:
16757698
6.

Cancer preventive phytochemicals as speed breakers in inflammatory signaling involved in aberrant COX-2 expression.

Surh YJ, Kundu JK.

Curr Cancer Drug Targets. 2007 Aug;7(5):447-58. Review.

PMID:
17691904
7.

Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis.

Tsuji S, Tsujii M, Kawano S, Hori M.

J Exp Clin Cancer Res. 2001 Mar;20(1):117-29. Review.

PMID:
11370818
8.

Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.

Sarkar FH, Adsule S, Li Y, Padhye S.

Mini Rev Med Chem. 2007 Jun;7(6):599-608. Review.

PMID:
17584158
9.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.

PMID:
17458893
10.

Metastases and their microenvironments: linking pathogenesis and therapy.

Sierra A.

Drug Resist Updat. 2005 Aug;8(4):247-57. Epub 2005 Aug 10. Review.

PMID:
16095951
11.

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

Chung LW, Baseman A, Assikis V, Zhau HE.

J Urol. 2005 Jan;173(1):10-20. Review.

PMID:
15592017
12.

COX-2 inhibitors act as radiosensitizer in tumor treatment.

Sminia P, Kuipers G, Geldof A, Lafleur V, Slotman B.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S272-5. Review.

PMID:
16507391
13.

Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.

Fosslien E.

Crit Rev Clin Lab Sci. 2000 Oct;37(5):431-502. Review.

PMID:
11078056
14.

RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.

Strillacci A, Griffoni C, Valerii MC, Lazzarini G, Tomasi V, Spisni E.

J Biomed Biotechnol. 2010;2010:828045. doi: 10.1155/2010/828045. Epub 2010 Jun 13. Review.

15.

Possible role of cyclooxygenase-2 inhibitors as anticancer agents.

Boonsoda S, Wanikiat P.

Vet Rec. 2008 Feb 2;162(5):159-61. Review. No abstract available.

PMID:
18245750
16.

Cyclooxygenase-2 inhibitors in colorectal cancer.

Stoehlmacher J, Lenz HJ.

Semin Oncol. 2003 Jun;30(3 Suppl 6):10-6. Review.

PMID:
12802790
17.

Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.

Arber N.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1852-7. doi: 10.1158/1055-9965.EPI-08-0167. Review.

18.

The role of COX-2 inhibition in breast cancer treatment and prevention.

Arun B, Goss P.

Semin Oncol. 2004 Apr;31(2 Suppl 7):22-9. Review.

PMID:
15179621
19.

Cyclooxygenase-2 as a target for anticancer drug development.

Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP.

Crit Rev Oncol Hematol. 2006 Jul;59(1):51-64. Epub 2006 Mar 13. Review.

PMID:
16531064
20.

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

Gately S, Li WW.

Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11. Review.

PMID:
15179620

Supplemental Content

Support Center